T-cell Precursor Acute Lymphoblastic Leukemia

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2018-07-26
Clinical Trial Update: Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL) [Phase 2]
A Phase 2 trial evaluating daratumumab for relapsed/refractory B-cell or T-cell precursor acute lymphoblastic leukemia has been withdrawn.